海正藥業(600267.SH):子公司獲得新獸藥註冊證書
格隆匯6月5日丨海正藥業(600267.SH)公佈,公司控股子公司浙江海正動物保健品有限公司(簡稱“海正動保公司”)收到中華人民共和國農業農村部核准簽發的非羅考昔咀嚼片《新獸藥註冊證書》,該新獸藥產品正式獲批二類新獸藥。非羅考昔咀嚼片是海正動保公司等11家公司共同研製獲批的二類新獸藥。非羅考昔咀嚼片適用於緩解犬骨關節炎及臨牀手術等引起的疼痛和炎症。
本次海正動保公司非羅考昔咀嚼片產品獲得二類《新獸藥註冊證書》,標誌着上述產品已符合《獸藥管理條例》和《獸藥註冊辦法》相關規定,有利於進一步推動公司在獸藥板塊的戰略佈局,提升公司市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.